Skip to main content

Table 1 Patient characteristics

From: Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors

  Step 1 Step 2
(n = 22) (n = 15)
Sex, Male 15 (68) 13 (87)
Age, year (mean [range]) 68 (56–78) 66 (49–76)
Weight, kg (mean [range]) 55 (40–85) 55 (42–70)
Height, cm (mean [range]) 162 (148–178) 165 (160–173)
Cancer typea
 Gastric 16 (73) 9 (60)
 Esophageal 4 (18) 6 (40)
 Colorectal 1 (5) 0 (0)
 NSCLC 2 (9) 0 (0)
 Thyroid 1 (5) 0 (0)
Primary tumor
 Present 11 (50) 8 (53)
Prior cancer therapy
 Chemotherapy 22 (100) 15 (100)
  No. of regimens (mean [range]) 4.4 (2–7) 4.5 (2–8)
 Surgery 10 (46) 8 (53)
 Radiation 3 (14) 4 (27)
EPHA2 expressionb
 0 10 (46) 0 (0)
 1+ 2 (9) 0 (0)
 2+ 6 (27) 13 (87)
 3+ 1 (5) 2 (13)
  1. N (%) unless otherwise stated
  2. Abbreviations: NSCLC, non–small-cell lung cancer; EPHA2, erythropoietin-producing hepatocellular receptor A2
  3. aPatients with more than one type of cancer were repeatedly counted
  4. bData were presented only for patients who have been examined for EPHA2 expression